Masimo First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Masimo (NASDAQ:MASI) First Quarter 2025 Results

Key Financial Results

• Revenue: US$372.0m (down 25% from 1Q 2024).
• Net income: US$47.2m (up 150% from 1Q 2024).
• Profit margin: 13% (up from 3.8% in 1Q 2024).
• EPS: US$0.87 (up from US$0.36 in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Masimo. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Masimo Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 8.1%.

Performance of the American Medical Equipment industry.

The company's shares are down 6.7% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Masimo you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.